NCT06172257Phase 3Completed

A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)

Study sponsor: Oculis

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-04-02Actual

Enrollment · participants401Actual

Source updated2026-05-01Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-05-01 · 3 fields changed

Completion date type changed

− Before

~~Estimated~~

+ After

Actual

Primary completion date changed

− Before

~~Apr 2026~~

+ After

2 Apr 2026

Recruitment status changed

− Before

~~Active not recruiting~~

+ After

Completed

Check registry source

Study details

Conditions studied

Diabetic Macular Edema

Treatments or interventions studied

Dexamethasone ophthalmic suspension (OCS-01)DrugAlso known as Dexamethasone
VehicleDrugAlso known as Placebo

Primary outcomes · main study measures

measure: Mean Change from Baseline in BCVA (Best Corrected Visual Acuity); description: Assessed using ETDRS (Early Treatment Diabetes Retinopathy Study) letters score: higher numbers on the ETDRS chart representing better visual acuity.; timeFrame: Week 52

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history